Knight Therapeutics (GUD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues reached $92.3M, up 13% year-over-year (18% at constant currency), driven by strong growth in the promoted portfolio and successful new product launches in Canada and Brazil.

• Record nine-month revenues of over CAD 271 million and adjusted EBITDA of over CAD 42 million.

• Regulatory approval of Minjuvi in Mexico, with launch expected in the first half of 2025, and continued expansion of the pipeline with multiple product submissions and launches.

• Adjusted EBITDA was $13.5M, down 13% year-over-year, reflecting increased investments in new launches and pipeline.

• Net income was $85K, a sharp decline from $9.6M in Q3 2023, mainly due to lower gains on financial instruments and higher expenses.

Financial highlights

• Q3 2024 revenues reached over CAD 91 million ($91.4M excluding IAS 29), up 12% year-over-year; constant currency revenue growth was 18%.

• Oncology and hematology portfolio revenues grew 18% to CAD 37 million; infectious disease portfolio revenues rose 16% to CAD 34 million.

• Gross margin was $45.0M (49% of revenues), flat as a percentage but up in dollars from Q3 2023; gross margin excluding IAS 29 was 47% in Q3 2024, down from 52% in Q3 2023.

• Adjusted EBITDA for Q3 was $13.5M (CAD 13.5 million), down 13% year-over-year, with adjusted EBITDA per share at $0.13, down 10%.

• Cash inflows from operations were $5 million in Q3 and $34.8 million year-to-date.

Outlook and guidance

• 2024 revenue guidance maintained at $355–$365 million, with adjusted EBITDA expected at approximately 16% of revenues, despite currency headwinds and generic competition.

• Pipeline of 18 products expected to generate over $150 million in peak sales.

• Guidance assumes no major supply disruptions, no new generic entrants on key brands, and stable pricing and FX.